157: A Phase II Trial Measuring the Integration of Stereotactic Ablative Radiotherapy (SABR) Plus Surgery in Operable Patients with Early Non-Small Cell Lung Cancer (Missile-NSCLC): Interim Safety Results. (September 2016)